InTrack Investment Management Inc Sells 1,385 Shares of Danaher Co. (NYSE:DHR)

InTrack Investment Management Inc decreased its holdings in Danaher Co. (NYSE:DHR) by 13.9% in the first quarter, HoldingsChannel reports. The institutional investor owned 8,584 shares of the conglomerate’s stock after selling 1,385 shares during the period. Danaher makes up 1.6% of InTrack Investment Management Inc’s portfolio, making the stock its 17th biggest position. InTrack Investment Management Inc’s holdings in Danaher were worth $1,760,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DHR. Norges Bank acquired a new position in Danaher during the fourth quarter worth $2,130,740,000. GAMMA Investing LLC grew its holdings in shares of Danaher by 24,958.2% in the 1st quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate’s stock worth $383,524,000 after purchasing an additional 1,863,381 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Danaher during the 4th quarter worth about $391,172,000. Two Sigma Advisers LP lifted its holdings in Danaher by 4,248.8% during the 4th quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate’s stock valued at $376,347,000 after purchasing an additional 1,601,800 shares during the last quarter. Finally, Capital World Investors boosted its position in Danaher by 32.7% in the fourth quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate’s stock valued at $1,460,215,000 after buying an additional 1,566,658 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Danaher Trading Up 1.7%

DHR opened at $202.63 on Wednesday. The firm has a 50 day simple moving average of $191.32 and a 200 day simple moving average of $211.72. Danaher Co. has a fifty-two week low of $171.00 and a fifty-two week high of $281.70. The company has a market cap of $145.02 billion, a price-to-earnings ratio of 38.38, a price-to-earnings-growth ratio of 2.66 and a beta of 0.77. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.26. The firm had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.58 billion. Danaher had a net margin of 16.33% and a return on equity of 10.82%. On average, sell-side analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.63%. Danaher’s dividend payout ratio is presently 24.85%.

Insider Buying and Selling at Danaher

In other news, EVP Christopher Paul Riley sold 15,805 shares of the company’s stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the sale, the executive vice president now directly owns 15,179 shares of the company’s stock, valued at $3,005,442. This represents a 51.01% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the transaction, the chairman now directly owns 3,105,808 shares in the company, valued at $611,036,665.92. The trade was a 28.70% decrease in their position. The disclosure for this sale can be found here. Insiders own 11.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on DHR shares. JPMorgan Chase & Co. dropped their price objective on shares of Danaher from $280.00 to $260.00 and set an “overweight” rating for the company in a report on Tuesday, April 22nd. UBS Group decreased their price target on Danaher from $275.00 to $240.00 and set a “buy” rating on the stock in a research report on Wednesday, April 23rd. Guggenheim reiterated a “buy” rating and issued a $250.00 price objective on shares of Danaher in a research report on Wednesday, April 23rd. Wolfe Research reduced their price objective on Danaher from $275.00 to $220.00 and set an “outperform” rating on the stock in a research note on Monday, April 7th. Finally, Wall Street Zen lowered Danaher from a “buy” rating to a “hold” rating in a research note on Monday. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $248.17.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.